Photo by nci from unsplash
11510Background: Polyclonal emergence of KIT secondary mutations (muts) is the main mechanism of imatinib (IM) progression in GIST. Although approved KIT inhibitors SU and RE each suppress only a s... Click to show full abstract
11510Background: Polyclonal emergence of KIT secondary mutations (muts) is the main mechanism of imatinib (IM) progression in GIST. Although approved KIT inhibitors SU and RE each suppress only a s...
Keywords:
rapid alternation;
alternation sunitinib;
study rapid;
gist;
phase study;
sunitinib regorafenib
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!